1. IVIVI TECHNOLOGIES, INC.
3/25/2017
THE
TECHNOLOGY
OF LIFE
IVIVI TECHNOLOGIES, INC.
NASDAQ
Symbol: IVVI

2. FORWARD-LOOKING STATEMENT
3/25/2017
FORWARD-LOOKING STATEMENT
Statements may be made in the course of this presentation with respect to the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future.  These are forward-looking statements that involve risks and uncertainties. It is important to note that the Company's actual results could differ materially from those projected in any forward-looking statements.  Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in the Company's filings with the Securities and Exchange Commission (“SEC”), including its Form 10-KSB for the fiscal year ended March 31, 2007 and other reports filed by the Company from time to time with the SEC.
3/25/ :33 AM

3. OVERVIEW NASDAQ: IVVI Recent Price: $5.25*
3/25/2017
OVERVIEW
NASDAQ: IVVI
Recent Price: $5.25*
52 Week Range: $ $6.64*
Market Capitalization: $55.6 million*
Total shares outstanding: 10.7 million (12/31/07)
* as of 02/22/08

4. 3/25/2017
HIGHLIGHTS
Proven, science-based “platform technology” – targeted electrotherapies for treatment of diseases
Non-invasive, non-pharmacologic treatment with no known side effects
FDA cleared to treat post-operative pain and edema in soft tissue
Published studies provide clinical evidence of efficacy
Growing number of partnerships and alliances
Multi-disciplinary team of scientists, engineers, physicians and executives
Large and diverse market opportunities
Current Future
Chronic wound care: $3.8 B Arthritic pain: $59 B Cosmetic surgery: $9.4 B Cardiovascular: $142.5 B
Stem cell therapy: $5.6 B
Orthopedics: $22.5 B

5. Case Studies Post-breast CA, 2 failed flaps,
3/25/2017
Case Studies
Post-breast CA, 2 failed flaps,
radiation treatment inhibits healing
Begin Ivivi PEMF Therapy Nine Weeks PEMF
Failed TRAM post breast reconstruction
Today we are already generating revenue in 2 markets - the Cosmetic and Bariatric Surgery Market, as well as the Chronic wound care market. In addition to these 2 markets we have a number of patents pending for 9 other specific vertical medical market opportunities including opthalmic, neurological, cardiac, orthopedics and others.
Thirteen Weeks PEMF
This slide contains before and after photographs showing the results of a single therapeutic use in humans.  These photographs are presented for illustration purposes only and do not guarantee similar results in all cases.

6. Indian Health Service Venous Stasis Ulcer
3/25/2017
Indian Health Service Venous Stasis Ulcer
admitted with severe lower body lymphedema with open venous wounds bilaterally acquired 8/06.  Tx started in wound care on 11/06. pmx of etoh with liver disease, decreased h&h, low albumin, asthma, and htn use of bilateral lymphedema pumps for two months until patient developed pul edema and was dc'd from pump s/p hospitalization.
wounds non healing in spite of conservative therapy until ivivi started on 6/15/07.
since 6/15 wt from 231 down to 213, wounds healed by 9/7/07, no htn, pt received arginade for albumin fluid shift and has not had reoccurance of wounds.
Venous stasis ulcer healed (3 wounds total)
at 12 weeks
Venous stasis ulcer unresponsive for
10 months
This slide contains before and after photographs showing the results of a single therapeutic use in humans.  These photographs are presented for illustration purposes only and do not guarantee similar results in all cases.

7. TECHNOLOGY VALIDATION AND CLINICAL EVIDENCE
3/25/2017
TECHNOLOGY VALIDATION AND CLINICAL EVIDENCE
Technology Validation:
CMS (Medicare) issued National Coverage Determination for PEMF for healing chronic wounds
AHCPR Federal Guidelines for Pressure Ulcers: “electrotherapies” only effective adjunctive treatment
ASAPS endorses 40% acceleration in healing in human burn model
Clinical Evidence:
72% reduction of sacral ulcers in paraplegics (Kloth, et al 1999)
700% reduction in swelling, acute ankle sprain (Pilla, et al 1996, 1999)
69% acceleration in tendon healing (Strauch, Pilla et al; The Journal of Hand Surgery, September 2006)
500% increase in new blood vessels (Roland, et al, 2000 and Weber, et al, 2004 Plastic and Reconstructive Surgery)
59% increase in surgical wound healing (Strauch, Pilla et al; Plastic and Reconstructive Surgery, August 2007)
40% acceleration in post-surgery recovery (ASAPS, 2001)
80% acceleration in post-surgery pain relief (Heden, 2007)
60% more significant soft-tissue repair than for bone growth (Akai M, Hayashi K meta-analysis, Bioelectromagnetics, 2002)

8. Ivivi Wheel of Innovation
3/25/2017
Ivivi Wheel of Innovation
Today we are already generating revenue in 2 markets - the Cosmetic and Bariatric Surgery Market, as well as the Chronic wound care market. In addition to these 2 markets we have a number of patents pending for 9 other specific vertical medical market opportunities including opthalmic, neurological, cardiac, orthopedics and others.

9. HOW ELECTROCEUTICALS WORK
3/25/2017
HOW ELECTROCEUTICALS WORK
Disease: Disruption of cellular electrochemistry
Healing: Restoration of key electrochemical processes that initiate the anti-inflammatory and growth factor cascades
First class of Electroceuticals
Enhance healing
Easy-to-use, FDA-cleared technology
Non-invasive
No known side effects
No effects on healthy tissue
Increase efficiency of natural anti-inflammatory response
All biological activity can be thought of as complex, inter-related cascades

10. EVOLUTION OF ELECTROCEUTICALS
3/25/2017
EVOLUTION OF ELECTROCEUTICALS
Pulsed Diathermy
High power PEMF to treat pain and edema (1930s)
Bone Growth Stimulators
PEMF to heal recalcitrant fractures (1974)
Standard of care in orthopedics
Targeted PEMFs
Target specific electrochemical processes (Calcium/CalModulin Binding)
Exploits science of electrochemistry for therapy (like MRI or CAT scan does for diagnosis)

11. EXAMPLE SIGNAL CONFIGURATION
Tendon Repair Model (Strauch, et al, JHS 2006)
(MRT) (SofPulse)

12. INTELLECTUAL PROPERTY
3/25/2017
INTELLECTUAL PROPERTY
Proprietary product development
Broad basic targeted PEMF patents
Picket-fence strategy – surround main patents with applications
16 issued and pending patents
Independent audit supports broad patent protection
Technology advancement: Mathematical Computer Modeling of Cellular Activity, Design, Testing, Manufacturing (like David’s). See the page from Steven
Second slide on patent protection

13. MARKET OPPORTUNITY CURRENT MARKETS FUTURE MARKETS
3/25/2017
MARKET OPPORTUNITY
CURRENT MARKETS
Chronic Wound Care: $3.8 Billion
Cosmetic Surgery: $9.4 Billion
FUTURE MARKETS
Osteoarthritic Pain: $59 Billion
Stem Cells and Tissue Regeneration: $5.6 Billion
Orthopedic Applications: $22.5 Billion
Angiogenesis and Vascularization: $142.5 Billion

14. STRATEGIC BUSINESS MODEL
3/25/2017
STRATEGIC BUSINESS MODEL
Validate
Therapy
Seed Target Markets
Negotiate
Partnerships
Beta market
testing
Initial
Marketing & Sales
Large Scale Distribution
Basic Science
For Example:
Wound Care
Rent products into acute care, LTACHs, VA, Skilled Nursing and Home Health Care
Independent distributors in select markets
Cosmetic Surgery
Sell disposable products to surgeons
Pass-through or mark-up
Clinical
Efficacy

15. COSMETIC SURGERY Partner: Allergan (AGN)
3/25/2017
COSMETIC SURGERY
Partner: Allergan (AGN)
Exclusive world-wide distribution (cosmetic, bariatric surgery only)
8-year term, minimum performance
Upfront licensing fee, advantageous revenue split
Initial 20,000 unit order received September 2007
Marketing underway, unit pricing ~$250
Market Opportunity > $500 million
650,000 Breast procedures
540,000 Facial Procedures
575,000 Liposuction/Abdominal
1,500,000 Non-surgical procedures (peels, micro-dermabrasion)
Clinical Support
80% acceleration in post-surgery pain relief, % reduction in pain medication (Heden 2007)
Post-facial surgery study underway
Post-adomonoplasty study anticipated
Capsular contracture study anticipated

16. WOUND CARE $3.3 Billion Market Opportunity (2004/2005 data)
3/25/2017
WOUND CARE
$3.3 Billion Market Opportunity (2004/2005 data)
5 million chronic wounds (US)
Long-Term Acute Care (LTACH): 440 / $15.6 million
Nursing Homes: 14,900 / $187 million
Hospitals: 4,900 / $176 million
Home Health Care: 7.6 million / $3 billion
Medicare Issued National Coverage Determination
Clinical Evidence, Cost Savings Driving Usage
72% decrease in wound size (Kloth, et al 1999)
LTACH competitive analysis driving unit gains
This slide contains before and after photographs showing the results of a single therapeutic use in humans.  These photographs are presented for illustration purposes only and do not guarantee similar results in all cases.

17. WOUND CARE Seeding Initiatives Ongoing Next Steps
3/25/2017
WOUND CARE
Seeding Initiatives Ongoing
Over 600,000 treatments n/k side effects
Rental + disposable model
9 sales people in NY and TX areas
Initial targets LTACHS, VA and Skilled Nursing Facilities
Next Steps
National Contracts with LTACHS
Regency Hospital Company 1/08
Product evaluations by other chains ongoing
Healing rates of 49-99% being achieved within weeks often after negative pressure therapy failed
Announce wound partners
DSI Renal 2/08
Additional discussions underway

18. CHRONIC KIDNEY DISEASE (CKD)
License agreement with DSI Renal, Inc
120 Dialysis Centers, 400 affiliated MDs, 8000 patients
High prevalence of diabetics, diabetic ulcers, and other vascular disorders
Founders are successful serial entrepreneurs in CKD
Phase I: DSI significant multi-center clinical trials
Double-blind, randomized placebo-controlled
150 patients
Primary end-points:
time to complete healing
degree of wound healing expressed as % total volume area healed at a specific time
% of non-healing wounds
Start by 6/30/08
Phase II: Sell technology into CKD market
20 million in US with CKD (Source: Kidney Foundation 2008)

19. 3/25/2017
CONSUMER PAIN RELIEF
21 million U.S. osteoarthritis patients*
Non-invasive, non-pharmacologic alternative to NSAID (e.g. aspirin)
No known side-effects
7-fold decrease in edema in acute injury (Pilla, et al 1999)
Current status
Prototypes developed
On-label regulatory strategy
510-K filing planned
Prescription strength
Over-the-counter
Studies for marketing claims planned
Partner discussions ongoing
$4 Billion in devices, Chronic pain afflicts 40 million Americans, Cost to economy over $100 Billion
No known side-effects, No known long-tem effects, Safe and effective
* American College of Rheumatology

20. ANGIOGENESIS Angiogenesis – creation of new blood vessels
3/25/2017
ANGIOGENESIS
Angiogenesis – creation of new blood vessels
Initial applications in Stem Cells, Tissue Regeneration, Neurology, and Cardiology
Arterial loops in rats at 8 weeks show 500% increase
Placebo-treated arterial loop
Actively treated arterial loop
Roland, et al., 2000 and Weber, et al., 2004 Plastic and Reconstructive Surgery
This slide contains before and after photographs showing research results in animal models.  These photographs are presented for illustrating research activities only and do not guarantee similar results in humans.

21. CARDIOVASCULAR ANGIOGENESIS
3/25/2017
CARDIOVASCULAR ANGIOGENESIS
Effects on injured heart in animal model
Without Treatment (sham)
With Treatment
Heart tissue near injury
Heart tissue near injury
New vessel growth
New vessel growth
Cleveland Clinic Study to be completed by 1st Q 2007
100% increase in new blood vessels in treated animals
Total global market opportunity: $142.5 Billion (AHA 2006)
This slide contains before and after photographs showing research results in animal models.  These photographs are presented for illustrating research activities only and do not guarantee similar results in humans.

22. Cleveland Clinic Florida
3/25/2017
Cleveland Clinic Florida
Initial human clinical trial
Randomized, double blinded, placebo controlled
End-stage ischemic heart disease
30 patients (15 active, 15 sham)
Endpoints
improvement in regional myocardial perfusion and function
improvement in angina and EX tolerance
Last patient completed trial January 2008
Preliminary results expected by June 30, 2008
$4 Billion in devices, Chronic pain afflicts 40 million Americans, Cost to economy over $100 Billion
No known side-effects, No known long-tem effects, Safe and effective

23. For the 12 months ended March 31 For the 9 months ended December 31
3/25/2017
OPERATING RESULTS
For the 12 months ended March 31
For the 9 months ended December 31
2007
2006
Total revenues
$1,182,340
$786,512
$1,080,347
$813,174
Research and dev.
$1,610,232
$1,334,637
$1,515,396
$1,644,029
Sales and marketing
$1,098,266
$1,152,947
$1,391,098
$913,086
General and admin.
$2,217,743
$2,055,865
$3,423,992
$2,694,857
Total oper. expenses
$7,269,363
$5,478,121
$6,586,684
$5,379,399
Operating loss
$(6,087,023)
$(4,691,609)
$(5,506,337)
$(4,566,225)
Just briefly on our operating results. Revenues in Fiscal 2007 which ended March 31 was approximately $1.2 million compared to $786,000 in fiscal and we had an operating loss of approximately $6.1 million. For the first two months of fiscal 2008, revenues were $687 thousand compared to $586 thousand. Year to date, for the first six months of fiscal 2008 we had an operating loss of $3.2 million.

24. 3/25/2017
BALANCE SHEETS
December 31, 2007
(unaudited)
March 31, 2007
(audited)
Total current assets
$9,301,864
$8,926,511
Total assets
$10,524,264
$9,303,473
Working capital
$8,194,640
$7,883,879
Total liabilities
$1,534,307
$1,516,590
Stockholders’ equity
$8,989,957
$7,786,883
Looking at our balance sheet, at September 30, 2007 we had current assets of $5.9 million and in October we raised an additional $4.8 million dollars in cash. With a current burn rate of $xxx,xxx per month we have sufficient capital for at least the next 12 months. Total shares outstanding after the offering are approximately 10.6 million. We do have outstanding warrants, which if exercised would bring in an additional $xx million and brings fully diluted shares outstanding to just over 16 million.

25. CAPITALIZATION 01/31/2008 Founders 1,495,000 Conversion of Notes
3/25/2017
CAPITALIZATION
01/31/2008
Founders
1,495,000
Conversion of Notes
2,061,783
ADM Tronics’ shares
3,250,000
IPO
Underwriters purchase option
Exercised Options
Exercised Warrants
Private Placement
2,500,000
250,000
52,125
82,235
1,000,000
Total shares outstanding
10,691,143
Warrants outstanding
2,643,191
Options outstanding
2,714,975
Number of fully diluted shares
16,049,309

26. 3/25/2017
SELECT MILESTONES
Oct. ‘06  Pricing of Initial Public Offering, Listing on AMEX
Nov. ‘06  Allergan Worldwide Distribution Agreement
Apr. ‘07  Health Canada Approval of Roma3 Electrotherapy Device for Treatment of Wounds
Jun. ‘07  CE Approval of Certain Electrotherapy Devices
Jun. ‘07  Completion of Patient Enrollment for Cardiac Clinical Trial at the Cleveland Clinic, Florida
Sep. ‘07  Received Initial 20,000 Unit Order from Allergan; Launch Underway
Oct. ‘07  Completed $5 million private placement
Jan. ‘08  Listing on NASDAQ Capital Market
Jan. ’08  Three Year Contract with Regency Hospital Company
Feb. ‘08  Research and Licensing Agreement with DSI Renal
Upcoming Milestones
Potential partnerships for additional market verticals
510(k) application for OTC and prescription pain technology
Cleveland Clinic cardiovascular study results
And now to conclude, I want to share with you some of the upcoming milestones to watch for as we move Ivivi to the next level.
We have made significant progress since our IPO in October of We announced our agreement with Allergan in November of 2006 and in September of 2007 received our first order signaling the start of the US launch. We received marketing approvals in Canada and the European Union for the wound care indication in April and June of 2007 respectively. We completed enrollment of our Cleveland Clinic Cardiac trial in June. In October of 2007, we completed a $5 million private placement at slightly above market price with no warrants - significantly strengthening our balance sheet. We also had several clinical trials published during the year as well.
Looking ahead, we hope to sign contracts with hospital chains to expand use of our technology in the treatment of chronic wounds and be able to announce a partner for the wound care space. We are also preparing to file a 510-K for a consumer pain device. And finally, we look forward to receiving the results of the Cleveland Clinic cardiac study which, if positive as we hope, will mean an even larger study and possible discussions with potential partners in this market as well.
We hope you found this presentation interesting and that you now know why we are excited about our company and our future. Thank you for your time in allowing us to tell you about Ivivi Technologies.

27. 3/25/2017
NASDAQ - IVVI